Catriona L Buchanan

This inventor holds 7 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Genzyme Corporation, Optein, Inc.. Active years: 2010-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Catriona L Buchanan. Retrieved from https://idiyas.com/inventor/catriona-l-buchanan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 2)

% Patents Active = 100.0

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 7.0

ph-index = 5

Forward Citations = 85(Granted Patents)

Location History:

Granta Park, GB (2010)
Sawston, GB (2013 - 2020)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2010-2020

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10781252 - Antibodies to TGF-β (2020-09-22),

2. 10174108 - Antibodies to TGF-beta (2019-01-08),

3. 9481726 - Antibodies to TGF-β (2016-11-01),

4. 9090685 - Antibodies to TGF-beta (2015-07-28),

5. 8591901 - Antibodies to TGF-β (2013-11-26),

6. 8383780 - Antibodies to TGFβ (2013-02-26),

7. 7723486 - Antibodies to TGF-β (2010-05-25),

Catriona L. Buchanan: Innovator in Antibody Development

Introduction

Catriona L. Buchanan is a prominent inventor located in Sawston, GB. With a remarkable portfolio of 7 patents, she has made significant contributions to the field of biotechnology, particularly in the development of antibody molecules targeting Transforming Growth Factor beta (TGF-β). Her innovative approaches are paving the way for advancements in therapeutic applications.

Latest Patents

Catriona's latest patents focus on antibody molecules that bind to Transforming Growth Factor beta (TGF-β). The inventions detail pan-specific antibody molecules that aim to neutralize TGF-β1, TGF-β2, and TGF-β3. The preferred embodiments within these patents include both whole antibodies, such as IgG (including IgG1 and IgG4), and antibody fragments, such as scFv, Fab, and dAb. These discoveries hold promise for various medical applications, showcasing Catriona's innovative capabilities in antibody research.

Career Highlights

Throughout her career, Catriona L. Buchanan has collaborated with some of the leading companies in the biotechnology industry, including Genzyme Corporation and Optein, Inc. Her expertise in developing targeted therapies has helped shape important advancements in biological treatments, particularly in the area of immunotherapy.

Collaborations

Catriona has worked alongside notable colleagues, including Steven R. Ledbetter and Celia Patricia Hart. These collaborations have contributed to the advancement of her research and the successful development of her patented technologies.

Conclusion

Catriona L. Buchanan's contributions to the field of antibody development highlight her status as an influential inventor. With a strong foundation built on innovative research and productive collaborations, she is well-positioned to continue impacting the biotechnology landscape with her groundbreaking inventions.

Profile summary based on public USPTO records.